Land: Jordanië
Taal: Engels
Bron: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)
Nilotinib 200 mg
شركة مستودع الأدوية الأردني - The Jordan Drugstore Co
L01XE08
Nilotinib 200 mg
200 mg
112 Caps
NOVARTIS PHARMA STEIN AG /SWI (سويسرا)
PRESCRIBING INFORMATION FOR HUMAN MEDICINES Novartis Pharma Schweiz AG Confidential Application no.: TASIGNA® COMPOSITION _Active substances _ Nilotinib as nilotinib hydrochloride monohydrate. _Excipients _ _Capsule contents – 50/150/200 mg capsules: _ Lactose monohydrate, (50/150/200 mg capsules: 39/117/156 mg), crospovidone, poloxamer, colloidal silicone dioxide, magnesium stearate. _Capsule shell_ _– 50 mg and 150 mg capsules_: Gelatin, titanium dioxide (E171), iron oxide (E172, red), iron oxide (E172, yellow). _Capsule shell –200 mg capsules_: Gelatin, titanium dioxide (E171), iron oxide (E172, yellow). _Printing ink – 50 mg and 150 mg capsules: _ Shellac (E904), iron oxide (E172, black), propylene glycol, ammonium hydroxide. _Printing ink – 200 mg capsules: _ Two different printing inks may be used on the 200 mg capsules. Printing ink a: Shellac (E904), iron oxide (E172, red), propylene glycol, ammonium hydroxide. Printing ink b: Shellac (E904), iron oxide (E172, red), propylene glycol, iron oxide (E172, black), titanium dioxide (E171). PHARMACEUTICAL FORM AND QUANTITY OF ACTIVE SUBSTANCE PER UNIT _50 mg hard capsules _ White to yellowish powder in hard gelatin capsules with red opaque cap and light yellow opaque body, size 4, with black radial imprint “NVR/ABL” on cap. _Capsules containing 150 mg nilotinib: _ PRESCRIBING INFORMATION FOR HUMAN MEDICINES Novartis Pharma Schweiz AG Confidential Application no.: White to yellowish powder in red opaque hard gelatin capsules, size 1, with black axial imprint “NVR/BCR”. _Capsules containing 200 mg nilotinib: _ White to yellowish powder in light yellow opaque hard gelatin capsules, size 0, with red axial imprint “NVR/TKI”. INDICATIONS/POTENTIAL USES • First-line treatment of adult patients and paediatric patients aged 2 years and over with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase. • Treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic or accelerated phase Lees het volledige document